Learn more about IDVYNSOTM (doravirine/islatravir), newly approved by the FDA.
Find out more about the newly FDA‑approved IDVYNSOTM (doravirine/islatravir) 100 mg/0.25 mg tablets.
The Merck Access Program (MAP) for IDVYNSO may be able to provide information about individual insurance coverage and out-of-pocket costs for IDVYNSO, co-pay assistance for eligible, privately-insured individuals, and how individuals may access IDVYNSO.